On March 23, SKB BIO-B (06990) officially disclosed its 2025 annual results. Impressively, this innovative pharmaceutical company, listed for less than three years, has already established a full-chain drug development process from "R&D - Clinical - Production - Commercialization" and successfully implemented a dual-driven model of "global collaboration + independent commercialization" for self-sustaining growth. This led to revenue of 2.058 billion yuan and a cash reserve of 4.559 billion yuan for the period, demonstrating to the market its strong endogenous growth capability and high predictability. Furthermore, this earnings report releases a strong positive signal - SKB BIO-B has formed a clearly structured, tiered pipeline of "three generations" of innovative assets. Combined with its mature "end-to-end" drug development capabilities and a market-validated commercialization pathway, the company has quietly pulled the trigger on its next phase of growth.
A Decisive Start: From Initial Victory to Therapeutic Expansion SKB BIO-B's first wave of pipeline assets consists of five competitive commercialized products. These include the TROP2 ADC sacituzumab govitecan (Jiatailai®) with Best-in-Class potential; the domestic HER2 ADC trastuzumab deruxtecan (Shutailai®), the first to outperform T-DM1 in a head-to-head trial for 2L+ HER2+ breast cancer; the PD-L1 monoclonal antibody tislelizumab (Ketailai®), the first approved for first-line treatment of nasopharyngeal carcinoma; and cetuximab N01 (Datailai®), demonstrating clinical equivalence to the originator drug Erbitux®. Additionally, the RET inhibitor lerociclib fumarate (Ningtailai®) for treating 1L+ RET+ non-small cell lung cancer is expected to gain approval within about a year. These products have opened a positive revenue stream for the company, marking a strong start. However, the company has not stopped there.
For this foundational commercial portfolio, SKB BIO-B's strategy is to deepen the moat of these existing assets through "combination therapies" and "indication expansion." The most notable asset is undoubtedly sacituzumab govitecan (Jiatailai®), subject to a business development transaction with global giant Merck & Co. With Merck's continued investment, it has advanced to 17 global Phase III clinical trials, becoming one of China's most globally influential pipeline assets. Such emphasis from the partner is linked to sacituzumab govitecan's outstanding performance in China. Over the past year, it gained approval for four indications, covering the two major cancer types of lung cancer and breast cancer. In lung cancer, based on excellent clinical data, it became the world's first TROP2 ADC approved for a lung cancer indication and was the first to demonstrate overall survival benefit in 2L EGFR-mutant NSCLC. In breast cancer, it is approved for treating Triple-Negative Breast Cancer, the most aggressive form, and the HR+/HER2- subtype, which has the largest patient population, establishing it as a "cornerstone therapy" from both severity and prevalence perspectives.
However, a true blockbuster lies not only in pioneering breakthroughs but also in continuously expanding boundaries. The company is vigorously advancing its use in combination with immunotherapies and small molecule targeted drugs to broaden its indication scope. Currently, the "ADC+IO" combination of sacituzumab govitecan plus Keytruda® for first-line treatment of NSCLC has successfully met the primary endpoint in a Phase III trial. By moving into earlier lines of therapy, sacituzumab govitecan transcends the traditional ADC market space limited to "later-line salvage therapy," advancing into first-line treatment with a larger patient base and longer treatment duration, even extending further into early-stage settings like neoadjuvant and adjuvant therapy, aiming for dominance in major cancers like lung cancer. Additionally, the company is exploring its application value in gynecological cancers, gastrointestinal cancers, and genitourinary cancers, further raising its market potential.
Beyond sacituzumab govitecan, other assets are also implementing the "combination therapy" strategy. The collaboration with Merck naturally pairs SKB BIO-B's ADC pipeline with a王牌 partner like Keytruda. The company also has the commercialized PD-L1 antibody tislelizumab and the PD-1/VEGF bispecific antibody SKB118, developed in collaboration with Crescent Biopharma. These molecules can perfectly synergize with SKB BIO-B's own ADC and novel DC platform assets, creating clinical value while extending product lifecycles. Targeted drugs like the EGFR antibody cetuximab N01 also have potential for combination with emerging small molecule products such as KRAS inhibitors, offering new approaches to address clinical resistance. This strategy of "permutations and combinations" of products with different mechanisms essentially builds a unique moat for these mature pipelines, significantly broadening their market potential.
Bridging the Gap: Five Molecules in Phase II, Core Pipeline Accelerates Capital markets are always sensitive to growth gaps; establishing confidence also hinges on the robustness of the mid-term pipeline. While the first batch of products advances steadily, SKB BIO-B's second wave of pipeline assets is poised for launch – represented by five ADC projects entering Phase II clinical trials: SKB315 (CLDN18.2 ADC), SKB410 (Nectin-4 ADC), SKB571 (novel bispecific ADC), SKB518 (potential FIC ADC), and SKB500 (novel ADC). This batch includes both novel ADCs based on validated targets with differentiated payload designs and cutting-edge innovative ADCs targeting potential first-in-class targets, balancing differentiated competitive advantages with innovation direction. Among them, SKB410 and SKB571 have previously been partnered with Merck & Co. It is worth noting that while SKB571 was not the first to enter the bispecific ADC race for its target, it has surpassed over 20 competitors to become the leading project in terms of development progress.
The current domestic ADC landscape is crowded with intense homogeneous competition. Breaking through in such a red ocean depends on the quality of underlying innovation and absolute speed of clinical advancement. The high-value licensing collaboration with Merck and the rapid clinical development pace have fully validated SKB BIO-B's molecular design capabilities meeting global top standards and its highly efficient development execution. This systematic, repeatedly proven success experience is being progressively transferred to the mid-term pipeline. This is SKB BIO-B's core bet for securing predictable growth over the next 3 to 5 years.
Escaping the Crowd: The Confidence to Aim for "World-Class" If the first two pipeline waves demonstrate SKB BIO-B's "execution capability" and "ability to deliver," then the third wave releases a strong signal of the underlying platform's "innovative capability."
On one hand, there is innovation in structure and mechanism. The company has a batch of novel ADC molecules densely entering clinical stages, carrying strong First-in-Class potential, allowing the company to completely escape the mire of traditional ADC competition. For instance, in the promising field of RDCs, SKB BIO-B's SKB107 initiated a Phase I trial for patients with advanced solid tumors and bone metastases in July last year. Global interest in RDCs is heating up, and SKB BIO-B has already secured a position. Additionally, SKB103, a novel bispecific TAA+IO mechanism ADC, can achieve precise tumor cell killing and tumor immune activation simultaneously, overcoming tumor heterogeneity and reducing drug resistance through synergistic multi-mechanisms, potentially opening up broad-spectrum anti-tumor treatment space for ADCs. The dual-payload ADC SKB565 introduces the novel concept of dual delivery, transporting both a toxin and an immunomodulator with synergistic mechanisms directly to tumor tissue for stronger, more durable tumor suppression. IND applications for both products have been accepted by the National Medical Products Administration.
On the other hand, there is the breaking of therapeutic boundaries. Beyond oncology, the vast non-oncology market represents another frontier. Leveraging technological accumulation from its large molecule, small molecule, and OptiDC™ platforms, SKB BIO-B is extending its reach into disease areas like autoimmunity and metabolism. Through diversified development of potential products like TSLP monoclonal antibodies, bispecific antibodies, and FXI/FXIa monoclonal antibodies, the company is expanding its therapeutic scope to asthma, COPD, and cardiovascular diseases. In March this year, the IND application for SKB575 for atopic dermatitis was approved by the NMPA, marking the acceleration of the company's pipeline beyond ADCs.
The most effective way to escape intense competition is to define new rules of the game. After establishing a systematic, cross-cycle layout in the ADC field, SKB BIO-B is steadily expanding into comprehensive therapeutic areas, powered by its underlying innovative momentum. This is the foundation of its confidence to truly advance towards becoming a "world-class Biopharma."
Conclusion Capital re-rating often occurs when a company transcends a single cycle and demonstrates systematic, self-sustaining capabilities. Today, SKB BIO-B has established a systematic value realization system based on its three-tiered pipeline gradient. Supported by end-to-end innovative product development and commercialization, as well as globally validated capabilities through partnerships with major international players: the company can aggressively expand its international footprint leveraging these globally competitive innovative assets; and conservatively, it can use continuous partnership deals to feed back into local innovation R&D and commercial sustainability, thereby endowing the company with high risk resilience and long-term valuation premium.
The charm of a truly mature Biopharma often lies in "predictable, sustained growth." Following sacituzumab govitecan, the biggest surprise SKB BIO-B brings to the market has evolved from anticipation of a single blockbuster to a mature system capable of continuously generating new growth engines. And as the flywheel of innovation spins faster, the major era for this Chinese pharmaceutical company may have just begun.
Comments